114 related articles for article (PubMed ID: 17431119)
1. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival.
Wilsker D; Bunz F
Mol Cancer Ther; 2007 Apr; 6(4):1406-13. PubMed ID: 17431119
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
3. Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1-dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic.
Herman-Antosiewicz A; Stan SD; Hahm ER; Xiao D; Singh SV
Mol Cancer Ther; 2007 Apr; 6(4):1249-61. PubMed ID: 17406033
[TBL] [Abstract][Full Text] [Related]
4. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.
de la Cruz-Morcillo MA; Valero ML; Callejas-Valera JL; Arias-González L; Melgar-Rojas P; Galán-Moya EM; García-Gil E; García-Cano J; Sánchez-Prieto R
Oncogene; 2012 Mar; 31(9):1073-85. PubMed ID: 21841826
[TBL] [Abstract][Full Text] [Related]
5. ATR mediates cisplatin resistance in a p53 genotype-specific manner.
Sangster-Guity N; Conrad BH; Papadopoulos N; Bunz F
Oncogene; 2011 Jun; 30(22):2526-33. PubMed ID: 21258400
[TBL] [Abstract][Full Text] [Related]
6. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition.
Caporali S; Levati L; Starace G; Ragone G; Bonmassar E; Alvino E; D'Atri S
Mol Pharmacol; 2008 Jul; 74(1):173-83. PubMed ID: 18413665
[TBL] [Abstract][Full Text] [Related]
7. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
8. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Ray S; Shyam S; Fraizer GC; Almasan A
Mol Cancer Ther; 2007 Apr; 6(4):1368-78. PubMed ID: 17431115
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation.
Kim YM; Lee EJ; Park SY; Cho KH; Kim JY; Pyo H
Mol Cancer Res; 2009 Jul; 7(7):1158-68. PubMed ID: 19584262
[TBL] [Abstract][Full Text] [Related]
10. D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Juang SH; Lung CC; Hsu PC; Hsu KS; Li YC; Hong PC; Shiah HS; Kuo CC; Huang CW; Wang YC; Huang L; Chen TS; Chen SF; Fu KC; Hsu CL; Lin MJ; Chang CJ; Ashendel CL; Chan TC; Chou KM; Chang JY
Mol Cancer Ther; 2007 Jan; 6(1):193-202. PubMed ID: 17237279
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T
J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation.
Wu X; Shell SM; Yang Z; Zou Y
Cancer Res; 2006 Mar; 66(6):2997-3005. PubMed ID: 16540648
[TBL] [Abstract][Full Text] [Related]
13. Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906.
Soares DG; Battistella A; Rocca CJ; Matuo R; Henriques JA; Larsen AK; Escargueil AE
Biochem J; 2011 Jul; 437(1):63-73. PubMed ID: 21470188
[TBL] [Abstract][Full Text] [Related]
14. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
15. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
16. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
Pan J; She M; Xu ZX; Sun L; Yeung SC
Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
[TBL] [Abstract][Full Text] [Related]
19. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
Liu X; Matsuda A; Plunkett W
Mol Cancer Ther; 2008 Jan; 7(1):133-42. PubMed ID: 18202016
[TBL] [Abstract][Full Text] [Related]
20. The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.
Iwata T; Uchino T; Koyama A; Johmura Y; Koyama K; Saito T; Ishiguro S; Arikawa T; Komatsu S; Miyachi M; Sano T; Nakanishi M; Shimada M
PLoS One; 2017; 12(5):e0178221. PubMed ID: 28558031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
